Sugi Predict

Sugi Predict / Compounds / SCHEMBL859709

SCHEMBL859709

SCHEMBL859709

C[Si](C)(C)CCOCn1ccc2c(-c3cnn(C(CC#N)C4CCN(c5cccc(Cl)n5)C4)c3)ncnc21

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 2/20 0.64
▸ TYRO3 Q06418 1/20 0.64
▸ JAK1 P23458 11/20 0.47
▸ JAK2 O60674 10/20 0.47
▸ MERTK Q12866 1/20 0.45
▸ JAK3 P52333 4/20 0.40
▸ ABL1 P00519 3/20 0.40
▸ TYK2 P29597 3/20 0.40
▸ DAPK3 O43293 2/20 0.40
▸ PAK4 O96013 2/20 0.40
▸ RET P07949 2/20 0.40
▸ LTK P29376 2/20 0.40
▸ CSNK1A1 P48729 2/20 0.40
▸ CLK2 P49760 2/20 0.40
▸ TNK2 Q07912 2/20 0.40
▸ ROCK1 Q13464 2/20 0.40
▸ DYRK1A Q13627 2/20 0.40
▸ IKBKE Q14164 2/20 0.40
▸ NTRK3 Q16288 2/20 0.40
▸ NTRK2 Q16620 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL860513 0.93 AXL (0.54) AXLTYRO3JAK1JAK2MERTK
SCHEMBL859065 0.91 AXL (0.52) AXLTYRO3JAK1JAK2MERTK
SCHEMBL859800 0.90 AXL (0.51) AXLTYRO3JAK1JAK2MERTK
SCHEMBL860258 0.90 AXL (0.51) AXLTYRO3JAK1JAK2MERTK
SCHEMBL859795 0.90 AXL (0.51) AXLTYRO3JAK1JAK2MERTK
SCHEMBL860086 0.89 AXL (0.49) AXLTYRO3JAK1JAK2MERTK
SCHEMBL861886 0.89 AXL (0.49) AXLTYRO3JAK1JAK2MERTK
SCHEMBL860504 0.89 AXL (0.48) AXLTYRO3JAK1JAK2MERTK
SCHEMBL3757088 0.89 AXL (0.50) AXLTYRO3JAK1JAK2MERTK
SCHEMBL860216 0.87 AXL (0.47) AXLTYRO3JAK1JAK2MERTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220378791-A1 JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES INCYTE CORPORATION 2022-12-01 — — US disclosed
CN-112494652-A JAK1 inhibitors for the treatment of myelodysplastic syndrome 因赛特公司 2021-03-16 — — CN disclosed
US-20210069193-A1 JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES INCYTE CORPORATION 2021-03-11 — — US disclosed
US-20190111058-A1 JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES INCYTE CORPORATION 2019-04-18 — — US disclosed
US-9334274-B2 N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors INCYTE HOLDINGS CORPORATION (US) 2016-05-10 — — US disclosed
US-20150246046-A1 JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES INCYTE CORPORATION 2015-09-03 — — US disclosed
US-20140221379-A1 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION (US) 2014-08-07 — — US disclosed
US-8716303-B2 N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors INCYTE CORPORATION (US) 2014-05-06 — — US disclosed
EP-2432555-B1 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-D]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-D]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORP (US) 2014-04-30 — — EP disclosed
EP-2432555-A1 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS Incyte Corporation (US) 2012-03-28 — — EP disclosed
WO-2010135650-A1 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION (US) 2010-11-25 — — WO disclosed
US-20100298334-A1 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION 2010-11-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298334-A1 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK1, JAK3, JAK2 AXL 449/4885TYRO3 25/4885JAK1 1/4885
US-20190111058-A1 JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES JAK1, JAK2, JAK3 AXL 1052/4885TYRO3 284/4885JAK1 1/4885
US-20220378791-A1 JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES JAK1, JAK2, JAK3 AXL 1052/4885TYRO3 284/4885JAK1 1/4885
US-20150246046-A1 JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES JAK1, JAK2, JAK3 AXL 1052/4885TYRO3 284/4885JAK1 1/4885
US-20210069193-A1 JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES JAK1, JAK2, JAK3 AXL 1052/4885TYRO3 284/4885JAK1 1/4885
US-20140221379-A1 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK1, JAK3, JAK2 AXL 449/4885TYRO3 25/4885JAK1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.